A phase III, multicentre, randomised, double-blind, placebo-controlled study, with open-label follow on, to evaluate the efficacy, safety and tolerability of PSD502 in subjects with Premature Ejaculation (PE)

ISRCTN	ISRCTN71916001
DOI	https://doi.org/10.1186/ISRCTN71916001
Secondary identifying numbers	PSD502-PE-004

Submission date: 04/01/2008
Registration date: 14/02/2008
Last edited: 30/06/2010

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Urological and Genital Diseases

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Plain English Summary

Not provided at time of registration

Contact information

Prof Wallace Dinsmore
Scientific

Consultant in GU Medicine
Royal Victoria Hospital
Belfast
BT12 6BA
United Kingdom

Phone	+44 (0)28 9089 4609
Email	wallacedinsmore@hotmail.com

Study information

Study design	This is a phase III, multicentre, randomised, double-blind, placebo-controlled study with open label follow on. Subjects will be randomised to PSD502 or placebo in a 2:1 ratio.
Primary study design	Interventional
Secondary study design	Randomised controlled trial
Study setting(s)	Hospital
Study type	Treatment
Participant information sheet	Not available in web format, please use the contact details below to request a patient information sheet
Scientific title
Study hypothesis	PSD502 is a metered dose spray containing a mixture of lidocaine and prilocaine which is under development by Plethora Solutions Ltd as a topical anaesthetic treatment for Premature Ejaculation (PE). The spray is applied to the glans penis a short time prior to intercourse. Most studies evaluating treatments for PE include intravaginal ejaculatory latency time (IELT) in the definition of PE. It has been estimated that PE affects 30 - 40% of the male population, but is paradoxically a condition for which they are least likely to seek help. Men with PE exhibit abnormal autonomic reflex pathways for the ejaculatory process. These include lower vibratory threshold to ejaculation, shorter bulbocavernous latency time and higher bulbocavernous evoked potentials. Reducing the heightened sensitivity of the glans penis with topical anaesthetics might therefore be a way of improving IELT, without adversely affecting the sensation of ejaculation. Although IELT is an objective measure of ejaculatory function it does not address the impact of therapy on patients well being and confidence in their sexual performance, which are important markers of treatment benefit. Therefore, if IELT is used as a sole efficacy measure it may not fully characterise the treatment benefit to the patient. For this reason, a patient reported outcome (PRO) known as the Index of Premature Ejaculation (IPE) will be used in this study in conjunction with IELT to evaluate efficacy. Thus the combination of the objective measure of ejaculatory latency with the PRO of IPE should be able to provide efficacy data which are representative of clinical benefit to the patient. The use of lidocaine, prilocaine and eutectic mixture of lidocaine and prilocaine (EMLA®) cream as topical anaesthetics is well established. Many years of experience of use in large numbers of patients, as well as comprehensive non-clinical safety testing programs for various formulations of lidocaine and prilocaine exist, to support their safety and tolerability. This information, together with the clinical data from three studies with PSD502 (ANAE-059-00, PSD502-PE-001, and PSD502-PE-003), suggest that PSD502 may have beneficial effects in reducing penile sensation and prolonging IELT, and its use is unlikely to be associated with significant clinical safety or tolerability concerns. The aim of this study is to provide additional placebo-controlled efficacy data to establish the clinical utility of PSD502 in the treatment of PE. In addition, long term open-label efficacy and safety data will be collected, to further support the registration package for PSD502 in the indication of treatment of PE. As of 29/01/2010, this record was updated; all amendments can be found under the relevant section with the above update date. At this time the actual trial dates were added to the record, the initial anticipated trial dates were as follows: Initial anticipated start date: 17/12/2007 Initial anticipated end date: 31/12/2008
Ethics approval(s)	Ethics approval received from the following institutional review boards: 1. Ethics Committee of FN Brno (Czech Republic) on the 12th September 2007 (ref: 073/07MEC) 2. Local Ethics Committee (Komisja Bioetyczna przy Okregowej Izbie Lekarskiej w Lodzi) (Poland) on the 14th November 2007 3. HSC Research Ethics Committee (UK) on the 30th October 2007 (ref: 07/NIR03/07) Added 29/01/2010: 4. Medical Research Council Ethics Committee for Clinical Pharmacology (Hungary) on the 29th January 2008
Condition	Premature ejaculation
Intervention	PSD502 is a metered dose aerosol spray that delivers a eutectic mixture of lidocaine and prilocaine. The placebo is a metered dose aerosol spray that is identical in appearance to the PSD502 spray and contains the same propellant. Subjects will be randomised to PSD502 or placebo in a 2:1 ratio. A single dose of PSD502 or placebo consists of three sprays applied to the glans penis. Subjects will continue for a three-month double blind treatment followed by 5 months open label treatment.
Intervention type	Drug
Pharmaceutical study type(s)
Phase	Phase III
Drug / device / biological / vaccine name(s)	PSD502
Primary outcome measure	To evaluate efficacy of treatment with PSD502 compared with placebo in subjects with PE as measured by: 1. Changes in mean IELT from baseline to during three-month double-blind treatment 2. Changes in selected IPE domains from baseline to month three
Secondary outcome measures	1. Change in selected IPE domains from baseline to three months 2. Proportion of subjects with short mean IELT during the three months of double-blind treatment 3. Change in mean IELT from baseline 4. Subject and partner PEP scores 5. Evaluation of the safety and tolerability of PSD502 compared with placebo in subjects with PE as measured by adverse event (AE) and serious adverse event (SAE) data for both the subject and his sexual partner, collected throughout the study
Overall study start date	18/12/2007
Overall study end date	16/07/2009

Eligibility

Participant type(s)	Patient
Age group	Adult
Lower age limit	18 Years
Sex	Male
Target number of participants	240 - 300
Participant inclusion criteria	Current information as of 29/01/2010: A subject will be considered suitable for the study if he fulfils all of the following criteria: 1. Willing and able to provide written informed consent 2. Male and aged 18 years and over 3. Diagnosed with PE according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria and International Society for Sexual Medicine (ISSM) definition 4. Has lifelong PE 5. Acceptable response to baseline premature ejaculation profile (PEP) 6. Subject must be in a stable heterosexual and monogamous relationship and the partner must provide consent 7. Acceptable sexual encounters in the baseline period Initial information at time of registration: A subject will be considered suitable for the study if he fulfils all of the following criteria: 1. Willing and able to provide written informed consent 2. Male and aged 18 years and over 3. Diagnosed with PE 4. Acceptable response to baseline premature ejaculation profile (PEP) 5. Subject must be in a stable heterosexual and monogamous relationship and the partner must provide consent 6. Acceptable sexual encounters in the baseline period
Participant exclusion criteria	A subject or his sexual partner where stated, who fulfils any of the following criteria will be excluded from the study: 1. Subject, or his sexual partner, has received an investigational (non-registered) drug within 30 days of screening 2. Subject has erectile dysfunction 3. The subject, or his sexual partner, has a physical or psychological condition that would prevent them from undertaking the study procedures, including, but not limited to, the following: 3.1. Urological disease 3.2. Ongoing significant psychiatric disorder not controlled by medication 4. Subject has safety testing abnormalities at the screening visit 5. Subjects taking excluded medications or receiving any treatment for PE 6. Subject, or his sexual partner, has a current history of alcohol or drug abuse 7. The subject, or his sexual partner, is unlikely to understand or be able to comply with study procedures, for whatever reasons 8. Subject, or his sexual partner, has known drug sensitivity to amide-type local anaesthetics 9. Subjects with pregnant partners 10. Subject with sexual partners of child-bearing potential and not using appropriate contraception 11. Subject, or his sexual partner, has a history of glucose-6-phosphate dehydrogenase (G-6-PD) deficiency or use of medications that would increase susceptibility to methemoglobinemia (e.g. anti-malarial agents)
Recruitment start date	18/12/2007
Recruitment end date	16/07/2009

Locations

Countries of recruitment

Czech Republic
Hungary
Northern Ireland
Poland
United Kingdom

Study participating centre

Consultant in GU Medicine

Belfast
BT12 6BA
United Kingdom

Sponsor information

Plethora Solutions Limited (UK)
Industry

4th Floor, 233 High Holborn
London
WC1V 7DN
United Kingdom

Phone	+44 (0)20 3077 5400
Email	mail@plethorasolutions.co.uk
Website	http://www.plethorasolutions.co.uk
"ROR"	https://ror.org/02y9vw172

Funders

Funder type

Industry

Plethora Solutions Limited (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
Publication and dissemination plan	Not provided at time of registration
IPD sharing plan

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2009		Yes	No